About: http://data.cimple.eu/news-article/2e07f00a6e27c5989989c6f7a623c739701a1cbf8fa6f607f2ce8363

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/2e07f00a6e27c5989989c6f7a623c739701a1cbf8fa6f607f2ce8363 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Europe's medicines regulator said Wednesday it will make a recommendation on the safety of Johnson & Johnson's coronavirus jab next week after US health authorities recommended pausing vaccinations over blood clot fears. The Amsterdam-based European Medicines Agency's announcement also comes as the US pharmaceutical company itself said it was delaying rollout of its vaccine on the continent. The "EMA is expediting this evaluation and currently expects to issue a recommendation next week," it said in a statement, after announcing last week a probe had been launched. "While its review is ongoing, EMA remains of the view that the benefits of the vaccine in preventing Covid-19 outweigh the risks of side effects," the medicines watchdog added. The US Food and Drug Administration and the Centers for Disease Control on Tuesday recommended a "pause" on the one-jab Covid-19 vaccine on worries over six reported cases of a rare type of blood clot in the United States. Johnson & Johnson then said it "made the decision to proactively delay the rollout of our vaccine in Europe," adding that it was reviewing the cases with European health authorities. Question marks now hover over the adenovirus-type vaccines produced by AstraZeneca and Johnson & Johnson after several blood clot cases in people who have received the shots. While the EMA has authorised AstraZeneca for all adults, many EU countries have taken the precaution of limiting its use to only older segments of the population. The EMA added that its probe into the "very rare" forming of blood clots from AstraZeneca's vaccine continued. "The review by EMA's human medicines committee (CHMP) will enable authorities to put the risks of Vaxzevria into the context of the benefits of ongoing vaccination campaigns," the agency said, referring to AstraZeneca's vaccine. jhe/dl
schema:headline	EMA to make finding on J&J vaccine next week
schema:mentions	Thrombosis European Medicines Agency Johnson & Johnson Medication Jab AstraZeneca European Union Vaccine United States Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Venous thrombosis Committee for Medicinal Products for Human Use
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-04-14 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	88 (xsd:integer)
http://data.cimple...entionsConspiracy	antivax conspiracy theory

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software